Osteosarcoma and chondrosarcoma: New signaling pathways as targets for novel therapeutic interventions

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 5, 2007, Pages 857-862

  Papachristou, Dionysios J ^a,b   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

Author keywords

Chondrosarcoma; Kinase; Osteosarcoma; Signal transduction; Transcription factor

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYCLIN DEPENDENT KINASE INHIBITOR 2C; CYCLIN DEPENDENT KINASE INHIBITOR 2D; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; METHOTREXATE; MYC PROTEIN; PICEATANNOL; PROTEIN P16INK4A; PROTEIN P53; RETINOBLASTOMA PROTEIN; RETINOID; RITUXIMAB; SCATTER FACTOR RECEPTOR; TEMSIROLIMUS; TRASTUZUMAB; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN;

CANCER GROWTH; CARTILAGE CELL; CHONDROSARCOMA; CLINICAL PATHWAY; DISEASE COURSE; HUMAN; ONCOGENE; ONCOGENE C MYB; ONCOGENE C MYC; OSTEOBLAST; OSTEOSARCOMA; PATHOGENESIS; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

CHONDROCYTES; CHONDROSARCOMA; HUMANS; MODELS, BIOLOGICAL; OSTEOBLASTS; OSTEOSARCOMA; PROTO-ONCOGENE PROTEINS; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34147110384     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2006.12.003     Document Type: Short Survey

References (21)

1. Andela V.B., Siddiqui F., Groman A., and Rosier R.N. An immunohistochemical analysis to evaluate an inverse correlation between Runx2/Cbfa1 and NF kappa B in human osteosarcoma. Journal of Clinical Pathology 58 (2005) 328-330
2. Bovée J.V.M.G., Clenton-Jansen A.-M., Taminiau A.H.M.T., and Hogendoorn P.C.W. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. The Lancet Oncology 6 (2005) 599-607
3. Coltella N., Manara M.-C., Cerisano V., Trusolino L., Di Renzo M.-F., Scotlandi K., et al. Role of MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. The FASEB Journal 17 (2003) 1162-1164
4. Fletcher C.D.M., Unni K.K., and Mertens F. Pathology and genetics of soft tissue and bone (2002), IRC Press, Lyon
5. Kronenberg H.M. Developmental regulation of the growth plate. Nature 423 (2003) 332-336
6. Longhi A., Errani C., De Paolis M., Mercuri M., and Bacci G. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treatment Reviews 32 (2006) 423-436
7. Morrison C., Radmacher M., Mohammed N., Suster D., Auer H., Jones S., et al. MYC amplification and polysomy 8 in chondrosarcoma: Array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome. Journal of Clinical Oncology 23 (2005) 9369-9376
8. Oda Y., Yamamoto H., Matsuda S., Tanaka K., Yokoyama R., Iwamoto Y., et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: Analysis within a group of patients, all of which developed lung metastasis. Modern Pathology 19 (2006) 738-745
9. Papachristou D.J., Batistatou A., Sykiotis G.P., Varakis J., and Papavassiliou A.G. Activation of the JNK-AP-1 signal transduction pathway is associated with the pathogenesis and progression of human osteosarcomas. Bone 32 (2003) 364-371
10. Papachristou D.J., Goodman M.A., Cieply K., Hunt J.L., and Rao U.M.N. Comparison of allelic losses in chondroblastoma and primary chondrosarcoma of bone and correlation with fluorescence in situ hybridization. Human Pathology 37 (2006) 890-898
11. Papachristou D.J., Papachristou G.I., Papaefthimiou O.A., Agnantis N.J., Basdra E.K., and Papavassiliou A.G. The MAPK-AP-1/-Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF. Histopathology 47 (2005) 565-574
12. Park H.R., Kim Y.W., Jung W.W., Kim H.S., Unni K.K., and Park Y.K. Evaluation of HER-2/neu status by real-time quantitive PCR in malignant cartilaginous tumors. International Journal of Oncology 24 (2004) 575-580
13. Sandberg A.A. Genetics of chondrosarcoma and related tumors. Current Opinion in Oncology 16 (2004) 342-354
14. Sandberg A.A., and Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: Osteosarcoma and related tumors. Cancer Genetics and Cytogenetics 145 (2003) 1-30
15. Swanton C. Cell-cycle targeted therapies. The Lancet Oncology 5 (2004) 27-36
16. Terek R.M., Healey J.H., Garin-Chesa P., Mark S., Huvos A., and Albino A.P. p53 mutations in chondrosarcoma. Diagnostic Molecular Pathology 1 (1998) 51-56
17. KIP1, is disrupted in osteosarcoma. The Journal of Cell Biology 167 (2004) 925-934
18. Vita M., and Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Seminars in Cancer Biology 16 (2006) 318-330
19. Vousden K.H. Activation of p53 tumor suppressor protein. Biochimica et Biophysica Acta 1602 (2002) 47-59
20. Yamaguchi T., Toguchida J., Wadayama B., Kanoe H., Nakayama T., Ishizaki K., et al. Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas. Anticancer Research 16 (1996) 2009-2015
21. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nature Reviews in Molecular and Cellular Biology 2 (2001) 127-137